Results 61 to 70 of about 21,990 (200)

High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactor

open access: yesBiotechnology and Bioengineering, Volume 123, Issue 11, Page 3165-3174, November 2026.
ABSTRACT The use of perfusion systems for the continuous cultivation of animal cells at high cell density (HCD) for the production of recombinant proteins, viruses, and viral vectors has many advantages. Besides an enhancement of volumetric productivity and high cell viability, the product quality can be improved through a steady‐state environment ...
Lennart Jacobtorweihe   +5 more
wiley   +1 more source

Implications of MicroRNAs in Oncolytic Virotherapy [PDF]

open access: yesFrontiers in Oncology, 2017
MicroRNAs (miRNAs) are an abundant class of small non-coding RNA molecules (~22 nt) that can repress gene expression. Deregulation of certain miRNAs is widely recognized as a robust biomarker for many neoplasms, as well as an important player in tumorigenesis and the establishment of tumoral microenvironments.
Xavier Bofill-De Ros   +5 more
openaire   +3 more sources

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

open access: yesAdvanced Science, Volume 13, Issue 58, 19 October 2026.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao   +10 more
wiley   +1 more source

Oncolytic Virus‐Engineered Extracellular Vesicles Rewire Glioblastoma Immunity

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Immunotherapy with oncolytic Herpes simplex virus type 1 (oHSV‐1) shows promise for glioblastoma; however, clinical benefit remains uncommon due to tumour‐ and host‐mediated immunosuppression, which limits immune targeting of residual glioblastoma stem‐like cells (GSCs). To address this barrier, extracellular vesicles (EVs) harvested from oHSV‐
Klaudia Kiel   +18 more
wiley   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta   +2 more
wiley   +1 more source

Oncolytic virotherapy - analysis, design, models [PDF]

open access: yes
The deliberate use of viruses as oncolytic (cancer killing) agents has become evident since initial observations tracing back to the early 20th century. However, clinical use of therapeutic viruses requires them to be safe and effective.
Bhatt, Darshak; id_orcid
core   +1 more source

Implications of immune cells in oncolytic herpes simplex virotherapy for glioma [PDF]

open access: yes, 2022
Despite current progress in treatment, glioblastoma (GBM) remains a lethal primary malignant tumor of the central nervous system. Although immunotherapy has recently achieved remarkable survival effectiveness in multiple malignancies, none of the immune ...
Yoo, Ji Young   +11 more
core   +1 more source

Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages

open access: yesJournal of Translational Medicine, 2023
Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy.
Zhen Shen   +7 more
doaj   +1 more source

Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Immune‐cell dynamics in the tumor microenvironment converge on four major barriers to effective therapy: failed immune access, defective antigen visibility and priming, loss of effector maintenance, and suppressive tissue remodeling. These barriers emerge from local hypoxic, cytokine, metabolic, and stromal signals.
Pin Guo   +8 more
wiley   +1 more source

Oncolytic polio virotherapy of cancer [PDF]

open access: yesCancer, 2014
Recently, the century‐old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late‐stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects ...
Michael C, Brown   +12 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy